Upload File

 · 2020. 6. 12. · 2.7.3.3-19 os (cabozantinib-2001 . full analysis set) recist 1.1 population)...

  • Home
  • Documents
  •  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
46

Upload: others

Post on 18-Nov-2020

6 views

Category:

Documents


0 download

Report

TRANSCRIPT

Page 1:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 2:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 3:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 4:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 5:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 6:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 7:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 8:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 9:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 10:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 11:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 12:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 13:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 14:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 15:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 16:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 17:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 18:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 19:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 20:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 21:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 22:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 23:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 24:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 25:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 26:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 27:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 28:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 29:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 30:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 31:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 32:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 33:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 34:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 35:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 36:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 37:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 38:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 39:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 40:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 41:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 42:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 43:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 44:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 45:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC
Page 46:  · 2020. 6. 12. · 2.7.3.3-19 OS (Cabozantinib-2001 . Full Analysis set) RECIST 1.1 population) 2.7.3.3-21 RECIST 1.1 population) 2.7.3.3-22 RECIST 1.1 . Full Analysis Set) IRC

Capturing Hyperprogressive disease with immune …...1 Capturing Hyperprogressive disease with immune checkpoint inhibitors using RECIST 1.1 criteria. Ignacio Matos1,2*, Juan Martin-Liberal1,

Welcome to the RECIST 1 - irrecist.comirrecist.com/recist/files/Recist-1.1-Fanbook.pdf · New response evalua-tion criteria in solid tumours: Revised RECIST guideline (version 1.1)

Criterios recist

Welcome to the RECIST 1 - irrecist.com · *Eisenhauer, E. A., et al. New response evalua-tion criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47

RECIST 1.1 Guidelines RECIST 1.1 Guidelines · a new lesi the id. RECIST 1.1 Guidelines RECIST 1.1 Guidelines Measurable Tumor Burden A maximum of 10 target lesions in total (and

How to evaluate tumor response? · LN is categorized as non-target lesion Number of target lesions: RECIST 1.0 ~ 1.1 may apply •Compared to target lesions for RECIST The longest

SEGUIMIENTO DE IMÁGENES CON CRITERIO RECIST (Response ... · RECIST 1.1, 2008 CRITERIOS DE RESPUESTA En lesiones blanco: Respuesta completa (CR): Desaparición de las lesiones blanco

RECIST 1.1: Applying the Rules - ONSclinicaltrial.vc.ons.org/file_depot/0-10000000/0-10000/3367/folder/... · • Interpretation of WHO guidelines vary amongst . groups ... • Neither

ISSN 2618-7124medradiology.moscow › d › 1364488 › d › no46_2018_recist_11.pdf · 2019-08-06 · Критерии recist 1.1 предназначены исключительно

RECIST guidelines

RECIST Response Evaluation Criteria In Solid Tumors

CDISC Journey in Solid Tumor using RECIST 1.1 Kevin Lee€¦ · RECIST!1.1! PD! Cycle5 20120301 13 00101001 NTRGRESP! Non\targetResponse! RECIST!1.1! NonCR/NonPD! Cycle5 20120301

referat recist

Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified

RECIST Overview. Introduction What is RECIST? RECIST Endpoints in Berenice Definitions Methods of Assessment Schedule of Assessments Evaluation

RECIST - Kryteria odpowiedzi radiologicznej na leczenie · RECIST - Kryteria odpowiedzi radiologicznej na leczenie Jarosław B. Ćwikła CSK MSWiA i CMKP Warszawa

CDISC Journey in Solid Tumor using RECIST 1.1 Kevin · PDF fileCDISC Journey in Solid Tumor using RECIST 1.1 Kevin Lee Statistician/CDISC Consultant/Programmer ! ... • SDTM • TU!:!Tumor!Iden1ficaon!

Challenges/Management of Oncogene Dependent …itocd.pekkip-congress.com/.../post-wclc-2015-brustugun.pdfPopulation: evaluable for response, data cut-off August 1, 2015; RECIST 1.1,

EVALUACIÓN DE LA RESPUESTA - academia.cat€¦ · RECIST guidelines (version 1.1). Eur J Cancer 45:228-247 . EVALUACIÓN DEL VOLUMEN (CARGA) TUMORAL RECIST y Macdonald Brain Tumors

CDISC Journey in Solid Tumor using RECIST 1 - cytel.com · CDISC Journey in Solid Tumor using RECIST 1.1 Kevin Lee PhUSE conference Oct 14th, 2013

CDISC Journey in Solid Tumor using RECIST 1 - · PDF fileCDISC Journey in Solid Tumor using RECIST 1.1 ... CDISC SDTM 4. CDISC ADaM 5. Conclusion 6. ... Progression Free Survival Analysis

CDISC Journey in Solid Tumor using RECIST 1 - PhUSE Wiki 2013 RG Presentations/RG02.pdf · CDISC Journey in Solid Tumor using RECIST 1.1 ... CDISC Tumor Domain ... OVRLRESP! Overall!Response!

criterios Recist-1.1-Fanbook

RECIST 1.1 still appropo? What are the alternatives? And ... SLIDES Munich10.17.18... · Recist 1.1 Reduced # of target lesions (max 5, 2 per organ) Revised assessment of lymph nodes

Comparison of RECIST 1.0 and 1.1 - Impact on Data Management

CRITERIOS WHO Y RECIST EN LA TC - IAEA

RECIST 1 1 PERSIGEHL 2019 v1...1 1 RECIST 1.1 PD Dr. Thorsten Persigehl Leitender Oberarzt Institut und für Diagnostische und Interventionelle Radiologie Universitätsklinikum Köln

Merck Imaging Tip Sheet for RECIST 1.1 and iRECIST MyLearning Courses... · 2018-01-16 · short axis ≥ 15mm Extra-nodal – use long axis ≥ 10 mm MSD approach to RECIST 1.1 allows

Multi trial evaluation of longitudinal tumor measurement (TM)-based metrics for predicting overall survival (OS) using the RECIST 1.1 data warehouse Background:

RECIST 1.1

UTILIDAD DE LOS CRITERIOS RECIST 1.1 EN LA …congreso.sordic.org.ar/uploads/2017/poster/2017_409_PE_Educacion.pdf · Criterios de respuesta De acuerdo a la respuesta terapéutica

Revisión de Tema: RECIST

Disposición 5278 - 15respuesta en tumores sólidos (Response Evaluation Criteria in Salid Tumors, RECIST), utilizando laversión 1.0 en elestudio Aylaversión 1.1 en losestudios ByC

New response evaluation criteria in solid tumours: Revised RECIST … · 2015. 11. 9. · 1.3. Process of RECIST 1.1 development The RECIST Working Group, consisting of clinicians

RECIST (Response Evaluation Criteria In Solid Tumors) › saglik › userfiles › file › RECIST... · 2013-05-08 · RECIST 1.1 Temel Değişiklikler RECIST • Maksimum 10 hedef